Updated analyses of Pomalyst/Imnovid for Multiple Myeloma- Celgene

Celgene International S�rl, announced that updated analyses from MM-003, the company�s phase III study of pomalidomide plus low-dose dexamethasone compared with high-dose dexamethasone in patients with refractory Multiple Myeloma who have failed therapy with both bortezomib and lenalidomide, administered either alone or in combination were presented at the American Society of Hematology Annual Meeting in New Orleans, La.

Pomalidomide is marketed as Pomalyst in the United States and Imnovid in the European Union.

It was previously reported that with a median follow-up of 10 months, pomalidomide plus low-dose dexamethasone significantly extended progression-free survival (PFS) (4.0 months vs 1.9 months, HR= 0.48, p<0.001) and overall survival os 12.7 months vs 8.1 months hr="0.74," p><0.028) compared with high-dose dexamethasone. the os benefit was observed despite 50 of the patients in the high-dose dexamethasone arm receiving subsequent pomalidomide. the overall response rate orr for the pomalidomide plus low-dose dexamethasone arm and high-dose dexamethasone arm was 31 vs. 10 p>< 0.001), respectively. The results were published in The Lancet Oncology -The Lancet Oncology, Vol. 14 No. 11 pp 1055-1066